This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Nektar Therapeutics

Drug Names(s): NKTR-181

Description: NKTR-181 is a novel mu-opioid analgesic investigational drug candidate engineeredusing Nektar's small molecule polymer conjugate technology. NKTR-181 has beendesigned to enter the central nervous system (CNS) at a substantially lower ratecompared to existing opioid therapies. By slowing the entry of the drug into theCNS, NKTR-181 has the potential to eliminate not only the euphoria that underliesopioid abuse liability and dependence, but also the serious CNS-related side effectsof respiratory depression and sedation. The unique molecular design of the polymerconjugate also prevents conversion of NKTR-181 into a free opioid or an abusable formof an opioid.

NKTR-181 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug